Multivalent minigene vaccines against infectious disease

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 1, 1999, Pages 16-21

  An, Ling Ling ^a   Whitton, J Lindsay ^b  

^a Ixsys Inc   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ANTIGEN PRESENTATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EXPRESSION VECTOR; GENE TARGETING; IMMUNOGENICITY; INFECTION; OPEN READING FRAME; REVIEW; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; BACTERIA; CD4-POSITIVE T-LYMPHOCYTES; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; EPITOPES; GENETIC VECTORS; HUMANS; MUTATION; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, COMBINED; VACCINES, DNA; VIRUSES;

EID: 0032955241     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Whitton JL Oldstone MBA: Class I MHC can present an endogenous peptide to cytotoxic T lymphocytes. J Exp Med (1989) 170:1033-1038.
2. Klavinskis LS, Whitton JL, Joly E, Oldstone MBA: Vaccination and protection from a lethal viral Infection: Identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope. Virol (1990) 178:393-400.
3. Oldstone MBA, Tishon A, Eddleston, De La Terre MJC, McKee TA, Whitton JL: Vaccination to prevent persistent viral Infection. J Virol (1990) 67:4372-4378.
4. del Val M, Schlicht HJ, Volkmer H, Messerle M, Reddehase MJ, Koszinowski UH: Protection against lethal cytomegalovirus Infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol (1991) 65:3641-3646.
5. Whitton JL, Sheng N, Oldstone MBA, McKee TA: A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J Vrol (1993) 67:348-352.
6. Suhrbier A: Multi-epitope DNA vaccines. Immunol Cell Biol (1997) 75:402-408.
7. Thomson, SA, Khanna R, Gardner J, Burrows SR, Coupar B, Moss DJ, Suhrbier A: Minimal epitopes expressed In a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: Implications for vaccine design. Proc Natl Acad Sci USA (1995) 92:5845-5849.
8. Rolph MS, Ramshaw IA: Recombinant viruses as vaccines and Immunological tools. Curr Opin lmmunol(1997) 9:517-524.
9. An LL, Whitton JL: A multivalent minigene vaccine, containing B cell, CTL, and Th epitopes from several microbes, Induces appropriate responses In vivo, and confers protection against more than one pathogen. J Virol (1997) 71:2292-2302. Shows that CD8+ T-cells, CD4+ T-cells, and antibodies can be induced by a 'string of beads' vaccine. See also [23].
10. Thomson SA, Elliott SL, Sherritt MA, Sproat KW, Coupar BE, Scalzo AA, Forbes CA, Ladhams AM, Mo XY, Tripp RA, Doherty PC, Moss DJ Suhrbier A: Recombinant polyepitope vaccines for the delivery of multiple CD8 eytotoxic T cell epitopes, J Immunol (1996) 157:822-826.
11. Toes RE, Hoeben RC, van der Voort EI, Ressing ME, van der Eb AJ, Mellef CJ, Offringa R: Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci USA (1997) 94:14660-14665.
12. Russmann H, Shams H, Poblete F, Fu Y, Galan JE, Donis RO: Delivery of epitopes by the Salmonella type III secretion system for vaccine development Science (1998) 281:565-568.
13. Darji A, Guzman CA, Gerstel B, Wachholz P, Timmis KN, Wehland J, Chakraborty T, Weiss S: Oral somatic transgene vaccination using attenuated S typhlmurium. Cell (1997) 91:765-775.
14. Tighe H, Corr M, Roman M, Raz E: Gene vaccination: Plasmid DMA Is more than Just a blueprint. Immunol Today (1998) 19:89-97.
15. Davis HL: Plasmid DNA expression systems for the purpose of Immunization. Curr Opin Biotechnol (1997) 8:635-640.
16. Hassett DE, Whitton JL: DNA Immunization. Trends In Microbiol (1996) 4:307-312.
17. Ciemik IF, Berzofsky JA, Carbone DP: Induction of cytotoxic T lymphocytes and antitumor Immunity with DNA vaccines expressing single T cell epitopes. J Immunol (1996) 156:2369-2375. An early demonstration that an ER localization signal could enhance minigene-induced CTL responses.
18. Corr M, Tighe H, Lee D, Dudler J, Trieu M, Brinson DC, Carson DA: Costimulatlon provided by DNA immunization enhances antitumor immunity. J Immunol (1997) 159:4999-5004.
19. Iwasaki A, Barber BH: Induction by DNA Immunization of a protective antitumor cytotoxic T lymphocyte response against a minimal-epitope-expressing tumor. Cancer Immunol Immunother (1998) 45:273-279.
20. Rodriguez F, An LL, Harkins S, Zhang J, Yokoyama M, Widera G, Fuller JT, Kincaid C, Campbell IL, Whitton JL DNA Immunization with minigenes: Low frequency of memory CTL and Inefficient antiviral protection are rectified by ublquitination. J Virol (1998) 72:5174-5181. Precursor CTL frequency and protective immunity are increased when a minigene CTL epitope is tagged with ubiquitin, enhancing its entry into the MHC class I pathway.
21. Thomson SA, Sherritt MA, Medveczky J, Elliott SL, Moss DJ, Fernando GJ, Brown LE, Suhrbier A: Delivery of multiple CD8 cytotoxic T cell epltopes by DNA vaccination. J Immunol (1988) 160:1717-1723. Ten contiguous CTL epitopes induce protective Immunity when delivered as a DNA vaccine.
22. Hanke T, Schneider J, Gilbert SC, Hill AV, McMichael A: DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: Immunogenicity in mice. Vaccine (1998) 16:426-435.
23. Yu, Z, Karem KL, Kanangat S, Manlckan E, Rouse BT: Protection by minigenes: A novel approach of DNA vaccines. Vaccine (1998) 16:1660-1667. DNA 'string of beads' vaccine Induces CD8+ T-cells, CD4+ T-cells, and antibodies and protective immunity. See also [9].
24. Zaghouanl H, Kuzu Y, Kuzu H, Brumeanu TD, Swiggard WJ, Steinman RM, Bona CA: Contrasting efficacy of presentation by major histocompatibility complex class I and class II products when peptides are administered within a common protein carrier, self immunoglobulin. Eur J Immunol (1993) 23:2746-2750.
25. Gilbert SC, Plebanski M, Harris SJ, Allsopp CE, Thomas R, Layton GT, Hill AV: A protein particle vaccine containing multiple malaria epltopes. Nat Biotechnol (1997) 15:1280-1284.
26. Brumeanu TD, Bot A, Bona CA, Dehazya P, Wolf L, Zaghouani H: Engineering of doubly antigenized immunoglobulins expressing T and B viral epitopes. Immunotechnology (1996) 2:85-95.
27. Casares S, Brumeanu TD, Bot A, Bona CA: Protective immunity elicited by vaccination with DNA encoding for a B cell and a T cell epitope of the A/PR/8/34 Influenza virus. Viral Immunol (1997) 10:129-136.
28. Gerioni, M, Xiong S, Zanetti M: Durable Immunity and Immunologic memory to a parasite antigen Induced by somatic transgene Immunization. Vaccine (1998) 16:293-297.
29. An LL, Pamer EG, Whitton JL: A recombinant minigene vaccine containing a nonameric cytotoxic-T-lymphocyte epitope confers limited protection against Listerla monocytogenes Infection. Infect Immun (1996) 64:1685-1693.
30. Whitton JL, Tishon A, Lewicki H, Gebhard JR, Cook T, Salvato MS, Joly E, Oldstone MBA: Molecular analyses of a fiveamino-acid cytotoxic T-lymphocyte (CTL) epitope: An Immunodominant region which Induces nonreciprocal CTL cross-reactivity. J Virol (1989) 63:4303-4310.
31. Volkmer H, Bertholet C, Jonjic S, Wittek R, Koszinowski UH: Cytolytic T lymphocyte recognition of the murine cytomegalovirus nonstructural Immediate-early protein pp89 expressed by recombinant vaccinia virus. J Exp Med (1987) 166:668-677.
32. van der Most, RG, Conception RJ, Oseroff C, Alexander J, Southwood S, Sidney J, Chesnut RW, Ahmed R, Sette A: Uncovering subdominant cytotoxic T-lymphocyte responses in lymphocytic choriomeningitis virus-infected BALB/c mice. J Virol (1997) 71:5110-5114.
33. b restricted subdominant cytotoxlc T-cell responses In lymphocytic choriomeningitis virus Infected mice. Virol (1998) 240:158-167.
34. Fu TM, Friedman A, Ulmer JB, Liu MA, Donnelly JJ: Protective cellular Immunity: Cytotoxic T-lymphocyte responses against dominant and recessive epitopes of Influenza virus nucleoprotein Induced by DNA Immunization. J Virol (1997) 71:2715-2721.
35. Chen Y, Webster RG, Woodland DL: Induction of CD8+ T cell responses to dominant and subdominant epitopes and protective Immunity to Sendal virus Infection by DNA vaccination. J Immunol (1998) 160:2425-2432.
36. Rodriguez F, Zhang J, Whitton JL: DNA Immunization: Ubiqultination of a viral protein enhances CTL induction, and antiviral protection, but abrogates antibody induction. J Virol (1997) 71:8497-8503.
37. Fu TM, Mylin LM, Schell TD, Bacik I, Russ G, Yewdell JW, Bennink JR, Tevethia SS: An endoplasmic reticulum-targeting signal sequence enhances the Immunogenicity of an Immunorecessive simian virus 40 large T antigen cytotoxic T-Lymphocyte epitope. J Virol (1998) 72:1469-1481.
38. Hsu SC, Obeld OE, Collins M, Iqbal M, Chargelegue D, Steward MW: Protective cytotoxic T lymphocyte responses against paramyxoviruses induced by epitope-based DNA vaccines: Involvement of IFN-γ. Int Immunol (1998) 10:1441-1447.
39. Thomson, SA, Burrows SR, Misko IS, Moss DJ, Coupar BE, Khanna R: Targeting a polyepitope protein Incorporating multiple class II- restricted viral epitopes to the secretory/endocytic pathway facilitates Immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design. J Virol (1998) 72:2246-2252. Targeting of minigene epitopes to the MHC class II pathway using LAMP signals.
40. Klinman DM, Yamshchikov G, Ishigatsubo Y: Contribution of CpG motifs to the Immunogenicity of DNA vaccines. J Immunol (1997) 158:3635-3639.
41. Hahn YS, Hahn CS, Braciale VL, Braclale TJ, Rice CM: CD8+ T cell recognition of an endogenously processed epitope Is regulated primarily by residues within the epitope. J Exp Med (1992) 176:1335-1341.
42. del Val M, Schlicht HJ, Ruppert T, Reddehase MJ, Koszinowski UH: Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on Its neighboring residues In the protein. Cell (1991) 66:1145-1153.
43. Yellen-Shaw AJ,.Wherry EJ, Dubois GC, Eisenlohr LC: Point mutation flanking a CTL epitope ablates In vitro and In vivo recognition of a full-length viral protein. J Immunol (1997) 158:3227-3234.
44. Yellen-Shaw AJ, Eisenlohr CL: Regulation of class I-restricted epitope processing by local or distal flanking sequence. J Immunol (1997) 158:1727-1733.
45. Bergman CC, Tong L, Cua R, Sensintaffar J, Stohlman S: Differential effects of flanking residues on presentation of epitopes from chimeric peptides. J Virol (1994) 68:5306-5310.
46. Yang B, Hahn YS, Hahn CS, Braclale TJ: The requirement for proteasome activity class I major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen. J Exp Mod (1996) 183:1545-1552.
47. Lopez D, del Val M: Cutting Edge: Selective Involvement of proteasomes and cystelne proteases in MHC class I antigen presentation. J Immunol (1997) 159:5769-5772.
48. Anton LC, Yewdell JW, Bennink JR: MHC class I-associated peptides produced from endogenous gene products with vastly different efficiencies. J Immunol(1997) 158:2535-2542. Quantitative analysis of the numbers of peptides produced from various minigenes and from a longer protein.
49. Weldt G, Deppert W, Utermohlen O, Heukeshoven J, Lehmann-Grube F: Emergence of virus escape mutants after Immunization with epitope vaccine. J Virol (1995) 69:7147-7151. A clear example of selection and evolution of viral 'CTL escape' mutants in vivo, in minigene-Immunized mice.
50. Mortara L, Letoumeur F, Gras-Masse H, Venet A, Guillet JG, Bourgault-Villada I: Selection of virus variants and emergence of virus escape mutants after Immunization with an epitope vaccine. J Virol (1998) 72:1403-1410.
51. Demotz S, Grey HM, Sette A: The minimal number of class II MHC-antigen complexes needed for T cell activation. Science (1990) 249:1028-1030.